uterine fibroids
Women's health · 2016–2024
3decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| linzagolix Treatment of symptomatic uterine fibroids in adult premenopausal women with moderate to severe symptoms who are unsuitable for, or have had an inadequate… | Jul 2024 | Not recommended | none received |
| ulipristal acetate Treatment of moderate to severe symptoms of uterine fibroids prior to planned surgery. | Mar 2017 | Not recommended | none received |
| ulipristal acetate Management of moderate to severe symptoms of uterine fibroids prior to planned surgery in adult women of reproductive age. | Jul 2016 | Not recommended | input received |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| linzagolixLinzagolix for treating moderate to severe symptoms of uterine fibroids | TA996 | recommended restricted | 2024-08 |
| relugolix estradiol norethisterone acetateRelugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | recommended | 2022-10 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.